Combined Approach Proves Optimal in Treatment of Extremity Veins

Article

Results from a registry covering the clinical experience of 777 patients have found that a clot-busting mechanical device in combination with thrombolytic drugs is faster, more ef¬fective, and safer than thrombolysis alone for treating deep venous thrombus.

 

Results from a registry covering the clinical experience of 777 patients have found that a clot-busting mechanical device in combination with thrombolytic drugs is faster, more ef¬fective, and safer than thrombolysis alone for treating deep venous thrombus.

Isolated thrombolysis involving mechanical thrombectomy and thrombolytic drugs can successfully treat clots in just a few hours, restore vein blood flow, relieve pain, and prevent future clotting, said principal investigator Dr. Gerard J. O'Sullivan, an interventional radiologist at University College Hospital in Galway, Ireland.

O'Sullivan and coauthor Dr. Mahmood K. Rahzavi, an interventionalist at St. Joseph Hospital in Orange County, California, reviewed a voluntary patient registry sponsored by the manufacturer of the Trellis peripheral infusion catheter (Bacchus Vascular, Santa Clara, California). The registry included 777 patients with lower and upper extremity DVT who were treated at four centers worldwide from February 2005 to February 2008.

The authors have no financial relationship with the firm, O'Sullivan said.

A total of 827 limbs with acute (28%), acute/chronic (44%), subacute (11%), subacute/chronic (12%), and chronic (6%) DVT were treated with Trellis-based isolated thrombolysis. The approach achieved significant or total thrombus removal in approximately 97% of acute patients. Almost all other subgroups achieved more than 90% treatment success. Results were reported at the 2008 Society of Interventional Radiology meeting.

Treatment with the mechanical thrombectomy device does not require general anesthesia and can be performed in less than two hours on average. Because it requires lower doses of thrombolytic drugs, it can reduce the risk of bleeding and other complications as well as treatment costs.

"This is a very significant advance in DVT treatment, which hasn't changed in more than 40 years," O'Sullivan said. "It's a shift of thinking and is going to change the way DVT is treated."

-By H.A. Abella

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.